Lentiviruses are a subgroup of retroviruses, characterized by their ability to cause a slow and progressive infection. The term "lenti" is derived from the Latin word "lentus," meaning slow, emphasizing the prolonged incubation period of these viruses. Human immunodeficiency virus (HIV), responsible for acquired immunodeficiency syndrome (AIDS), is the most well-known lentivirus. Lentiviruses have a single-stranded RNA genome that is reverse transcribed into DNA upon entering host cells, integrating into the host genome for persistent infection. Lentiviruses exhibit a broad host range, infecting various species, including humans and other mammals. Their ability to infect both dividing and non-dividing cells distinguishes lentiviruses from other retroviruses. Research on lentiviruses has led to significant insights into viral replication, host interactions, and the development of gene therapy vectors. Lentiviral vectors are used in biotechnology and gene therapy applications due to their ability to efficiently deliver genetic material into target cells.
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : Homology analysis of MPXV and VACV peptides underscores the need to consider both MPXV clades for vaccine development
Lara Isis Teodoro, Mayo Clinic, United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : High seroprevalence of RSV antibodies in adults indicates potential undetected transmission and requires further public health assessment
Lara Isis Teodoro, Mayo Clinic, United States
Title : The role of immunity in the pathogenesis of SARS-COV-2 and in the protection generated by COVID-19 in different age groups
Ahmed Abdulazeez, BHRUT Trust, United Kingdom
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Tubercular disease in children: Optimizing treatment strategies through disease insights
Elena Chiappini, University of Florence, Italy
Title : Approaches towards developing and establishing a biomanufacturing research & development, and manufacturing industry in Zimbabwe: A review of the need, potential funding sources, policy development and implementation
Elliot Nyagumbo, Midlands State University, Zimbabwe
Title : Racial disparities in pediatric pneumonia in Brazil: The role of structural racism forging inequalities in acess to vaccines
Livia Daflon Silva, Federal University of State of Rio de Janeiro, Brazil
Title : Capillary electrophoresis for adjuvanted multivalent recombinant vaccine purity determination
Ashley Prout, Merck, United States